{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T14:01:09Z","timestamp":1785506469111,"version":"3.56.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Rare diseases affect a small percentage of the population but collectively impact millions worldwide. In the Middle East, the challenges are intensified by regional factors such as high rates of consanguinity, sociocultural stigma, limited diagnostic capacity, and inadequate healthcare infrastructure. These challenges often lead to delayed diagnoses, restricted access to treatment, and poor quality of life for affected individuals and their families.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The Rare Advocacy Council conducted two 1.5-hour virtual expert panels involving 14 regional and international stakeholders (5 clinicians, 4 patient advocates, and 5 international academic experts) to identify and prioritize the challenges of managing rare diseases in the Middle East region. Discussions were organized across four domains: disease recognition and diagnosis, the patient journey and continuum of care, access to timely diagnostics, and access to adequate treatment, followed by structured online voting (involving only clinicians and patient advocates;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20099), discussions focused on prioritization, and a descriptive follow-up survey to identify the most critical barriers and propose actionable solutions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Key challenges identified included the lack of national disease registries, limited public awareness, underrepresentation of patient voices in decision-making, fragmented multidisciplinary care, and restricted access to diagnostics and advanced therapies. Top priorities included developing national registries, enhancing media-driven education, strengthening collaboration among care providers, and improving treatment accessibility through policy reforms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Effective management of rare diseases in the Middle East requires a coordinated, patient-centered approach. Strengthening health system infrastructure, investing in education, and aligning policy with patient needs are essential for sustainable improvement. Collaborative action among policymakers, healthcare providers, and advocacy groups can significantly advance care delivery and improve outcomes for individuals living with rare diseases.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04469-1","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:09:12Z","timestamp":1785503352000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Management of patients with rare diseases in the Middle East: challenges &amp; opportunities \u2013 insights from the Rare Advocacy Council"],"prefix":"10.1186","volume":"21","author":[{"given":"Agn\u00e8s","family":"Farrugia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Tarawah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa","family":"Al Yamani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8140-8694","authenticated-orcid":false,"given":"Carla","family":"Abou Selwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dania","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Wolfs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorica","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hafiz Mosa Ali","family":"Malhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"De Graaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"\u017divkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youmna","family":"Ouraybi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zakareya","family":"Al Kadhem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nafisa","family":"Tawfiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Davelaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha Mohamed Mahmoud","family":"Abdelbaky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"issue":"2","key":"4469_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","volume":"28","author":"S Nguengang Wakap","year":"2020","unstructured":"Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, Murphy D, Le Cam Y, Rath A. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet. 2020;28(2):165\u201373. https:\/\/doi.org\/10.1038\/s41431-019-0508-0.","journal-title":"Eur J Hum Genet"},{"key":"4469_CR2","unstructured":"Global genes. RARE disease facts. 2024. Available from: [Last accessed January 20, 2025]. https:\/\/globalgenes.org\/rare-disease-facts\/. Accessed 20 Jan 2025."},{"issue":"1","key":"4469_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13073-023-01157-8","volume":"15","author":"M El Naofal","year":"2023","unstructured":"El Naofal M, Ramaswamy S, Alsarhan A, Nugud A, Sarfraz F, Janbaz H, Taylor A, Jain R, Halabi N, Yaslam S, et al. The genomic landscape of rare disorders in the Middle East. Genome Med. 2023;15(1):5. https:\/\/doi.org\/10.1186\/s13073-023-01157-8.","journal-title":"Genome Med"},{"key":"4469_CR4","doi-asserted-by":"publisher","unstructured":"Boycott KM, Lau LP, Cutillo CM, Austin CP. International collaborative actions and transparency to understand, diagnose, and develop therapies for rare diseases. EMBO Mol Med. 2019;11(5). https:\/\/doi.org\/10.15252\/emmm.201910486.","DOI":"10.15252\/emmm.201910486"},{"issue":"11","key":"4469_CR5","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1038\/s41436-021-01241-7","volume":"23","author":"AA Navarrete-Opazo","year":"2021","unstructured":"Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. Genet Med. 2021;23(11):2194\u2013201. https:\/\/doi.org\/10.1038\/s41436-021-01241-7.","journal-title":"Genet Med"},{"issue":"1","key":"4469_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13023-021-02061-3","volume":"16","author":"A Tisdale","year":"2021","unstructured":"Tisdale A, Cutillo CM, Nathan R, Russo P, Laraway B, Haendel M, Nowak D, Hasche C, Chan CH, Griese E, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis. 2021;16(1):429. https:\/\/doi.org\/10.1186\/s13023-021-02061-3.","journal-title":"Orphanet J Rare Dis"},{"key":"4469_CR7","unstructured":"The Lewin Group IfEFfRD. The cost of delayed diagnosis in rare disease: a health economic study. 2023. Available from: https:\/\/everylifefoundation.org\/wp-content\/uploads\/2023\/09\/EveryLife-Cost-of-Delayed-Diagnosis-in-Rare-Disease_Final-Full-Study-Report_0914223.pdf. Accessed 20 Jan 2025."},{"issue":"3","key":"4469_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41588-022-01037-8","volume":"54","author":"Rare diseases, common challenges","year":"2022","unstructured":"Rare diseases, common challenges. Nat Genet. 2022;54(3):215\u2013215. https:\/\/doi.org\/10.1038\/s41588-022-01037-8.","journal-title":"Nat Genet"},{"issue":"1","key":"4469_CR9","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s13073-021-01003-9","volume":"13","author":"AN Abou Tayoun","year":"2021","unstructured":"Abou Tayoun AN, Fakhro KA, Alsheikh-Ali A, Alkuraya FS. Genomic medicine in the Middle East. Genome Med. 2021;13(1):184. https:\/\/doi.org\/10.1186\/s13073-021-01003-9.","journal-title":"Genome Med"},{"issue":"1","key":"4469_CR10","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13073-020-00821-7","volume":"12","author":"AN Abou Tayoun","year":"2020","unstructured":"Abou Tayoun AN, Rehm HL. Genetic variation in the Middle East-an opportunity to advance the human genetics field. Genome Med. 2020;12(1):116. https:\/\/doi.org\/10.1186\/s13073-020-00821-7.","journal-title":"Genome Med"},{"issue":"1","key":"4469_CR11","doi-asserted-by":"publisher","first-page":"e1051","DOI":"10.1002\/mgg3.1051","volume":"8","author":"T Ben-Omran","year":"2020","unstructured":"Ben-Omran T, Al Ghanim K, Yavarna T, El Akoum M, Samara M, Chandra P, Al-Dewik N. Effects of consanguinity in a cohort of subjects with certain genetic disorders in Qatar. Mol Genet Genomic Med. 2020;8(1):e1051. https:\/\/doi.org\/10.1002\/mgg3.1051.","journal-title":"Mol Genet Genomic Med"},{"key":"4469_CR12","doi-asserted-by":"publisher","unstructured":"Adachi T, El-Hattab AW, Jain R, Nogales Crespo KA, Quirland Lazo CI, Scarpa M, Summar M, Wattanasirichaigoon D. Enhancing equitable access to rare disease diagnosis and treatment around the world: a review of evidence, policies, and challenges. Int J Environ Res Public Health. 2023;20(6). https:\/\/doi.org\/10.3390\/ijerph20064732.","DOI":"10.3390\/ijerph20064732"},{"key":"4469_CR13","unstructured":"World Health Organization (WHO). Rare diseases: a global health priority for equity and inclusion. 2025. Available from: https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA78\/A78_R11-en.pdf. Accessed 16 Dec 2025."},{"key":"4469_CR14","unstructured":"International Rare Diseases Research Consortium (IRDiRC). Vision and goals. 2025. Available from: https:\/\/irdirc.org\/vision-and-goals\/. Accessed 16 Dec\u00a0 2025."},{"key":"4469_CR15","unstructured":"EURORDIS. Our strategy & impact. 2021. Available from: https:\/\/www.eurordis.org\/who-we-are\/our-strategy-impact\/. Accessed 16 Dec 2025."},{"key":"4469_CR16","unstructured":"Ministry for Solidarity and Health and the Ministry for Higher Education RaIF. French national plan for rare diseases 2018\u20132022. Available from: https:\/\/sante.gouv.fr\/IMG\/pdf\/pnmr3_-_en.pdf?utm [Last accessed December 16, 2025]."}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04469-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04469-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04469-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:09:14Z","timestamp":1785503354000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04469-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4469"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04469-1","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have received honoraria from Pfizer Inc. for participating in the Rare Advocacy Council.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"260"}}